Article Per Year (5 Year)
p-Index From 2021 - 2026
0
P-Index
This Author published in this journals
All Journal Jurnal Farmasi Udayana
Lindae Novianae
Unknown Affiliation
Medicine & Pharmacology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Ligan SV2A sebagai Terapi Epilepsi Lindae Novianae; Sumarno Sumarno
Jurnal Farmasi Udayana Vol. 9, No. 1, Tahun 2020
Publisher : Departement of Pharmacy, Faculty of Mathematics and Natural Science, Udayana University

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (566.051 KB) | DOI: 10.24843/JFU.2020.v09.i01.p01

Abstract

Epilepsi described a condition in which a person has recurrent seizures due to a chronic, underlying process. Seizure is a transient occurrence of sign or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. Seizure are a result of a shift in the normal balance of excitation and inhibition within the CNS. The ILAE has released a 2017 version of seizure-type classification, basic and expanded version. Seizure classification is an important element in designing the treatment plan, because some epileptic drugs have different activities against various seizure types. Antiepileptic drugs to act primaryli by blocking the initiation or spread of seizures through a variety of mechanism. The newer mechanism of antiepileptic drugs is binding to the glycoprotein SV2A. This paper discuss SV2A ligand Levetiracetam and brivaracetam for the treatment of epilepsy. Discussed include aspect pharmacology, some clinical studies about efficasy, safety, and tolerability, so it can provide information related to the new drug SV2A ligand in determining drug choices for the treatment of epilepsy. Keywords: epilepsy, brivaracetam, levetiracetam, seizure, SV2A ligands
Co-Authors Sumarno Sumarno